Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT

Jochen Hammes, Philipp Taeger and Alexander Drzezga
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 87;
Jochen Hammes
2Department of Nuclear Medicine University Hospital Cologne Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Taeger
1Uniklinik Koln Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Drzezga
3University Hospital of Cologne Cologne Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

87

Objectives: PSMA PET/CT has a high diagnostic accuracy for lesion detection in metastatic prostate cancer (MPC), including bone metastases. Novel therapeutic approaches require valid biomarkers for standardized disease staging, progression and therapy response. Here, we present EBONI (Evaluation of Bone Involvement), a software to automatically quantify bone metastasis load in PSMA PET/CT. Lesion quantity, mean and maximum lesional standardized uptake value (SUV), Z-Score and percentage of affected bone volume are determined. Furthermore, SUV-weighted tumor volume is calculated for each single lesion. Methods: EBONI was developed in the MATLAB environment to ensure platform independence. The code basis is open source and the tool is made freely available. To validate EBONI, results of automated quantification of 38 PSMA PET/CT scans with different levels of bone involvement were compared to visual expert reading. Influence of SUV threshold (SUVT) and Hounsfield unit thresholds (HUT) were analyzed. Results: A very high correlation between bone lesion quantity as determined visually and automatically was found (SUVmax: r2=0.97, SUVmean: r2=0.88, lesion count: r2=0.97). HUT had no significant influence while a SUVT of 2.5 proved optimal for automated lesion quantification. Non-specific uptake e.g. in abdominal organs and the urinary tract are eliminated systematically (Fig. 1). The amount of false positive tissue misclassification is low, occurred mainly around the salivary and lacrimal gland and could easily be corrected for. There were no false negative ratings

Conclusions: EBONI-analysis is robust, quick (<3 minutes per scan) and 100% reproducible. It allows rater independent quantification of bone metastasis in MPC. It provides lesion quantification equivalent to visual assessment and complementary information. It can be easily implemented as an add-on to visual analysis of PSMA PET/CT scans and has the potential of reducing turnaround time.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT
Jochen Hammes, Philipp Taeger, Alexander Drzezga
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 87;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT
Jochen Hammes, Philipp Taeger, Alexander Drzezga
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 87;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Prostate Cancer Imaging I

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients
Show more Prostate Cancer Imaging I

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire